Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals has a breakthrough drug for stroke and TBI. The Co. has approximately $2MM in investor commitments to this round.
Remedy Pharmaceuticals’ drug, RP-1127, mitigates the damaging after-effects of stroke and traumatic brain injury (TBI). The US & EU market for these indications is estimated at over $4Billion. Many previous attempts to treat stroke and TBI focused on neurons and required the molecule to cross what is called the “Blood Brain Barrier”—and all failed. Remedy’s drug works in a completely different manner— on the capillaries that comprise the